- Home
- KLTOW vs RVNC Comparison
KLTOW vs RVNC Comparison
Compare KLTOW & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTOW
- RVNC
- Stock Information
- Founded
- KLTOW N/A
- RVNC 1999
- Country
- KLTOW United States
- RVNC United States
- Employees
- KLTOW N/A
- RVNC N/A
- Industry
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- KLTOW Health Care
- RVNC Health Care
- Exchange
- KLTOW Nasdaq
- RVNC Nasdaq
- Market Cap
- KLTOW N/A
- RVNC 320.5M
- IPO Year
- KLTOW 2022
- RVNC 2014
- Fundamental
- Price
- KLTOW $0.03
- RVNC $3.09
- Analyst Decision
- KLTOW
- RVNC Hold
- Analyst Count
- KLTOW 0
- RVNC 9
- Target Price
- KLTOW N/A
- RVNC $8.45
- AVG Volume (30 Days)
- KLTOW N/A
- RVNC 3.6M
- Earning Date
- KLTOW N/A
- RVNC 11-07-2024
- Dividend Yield
- KLTOW N/A
- RVNC N/A
- EPS Growth
- KLTOW N/A
- RVNC N/A
- EPS
- KLTOW N/A
- RVNC N/A
- Revenue
- KLTOW N/A
- RVNC $256,945,000.00
- Revenue This Year
- KLTOW N/A
- RVNC $11.28
- Revenue Next Year
- KLTOW N/A
- RVNC $27.21
- P/E Ratio
- KLTOW N/A
- RVNC N/A
- Revenue Growth
- KLTOW N/A
- RVNC 25.82
- 52 Week Low
- KLTOW N/A
- RVNC $2.30
- 52 Week High
- KLTOW N/A
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- KLTOW N/A
- RVNC 33.47
- Support Level
- KLTOW N/A
- RVNC $3.06
- Resistance Level
- KLTOW N/A
- RVNC $3.09
- Average True Range (ATR)
- KLTOW 0.00
- RVNC 0.11
- MACD
- KLTOW 0.00
- RVNC 0.02
- Stochastic Oscillator
- KLTOW 0.00
- RVNC 6.90
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.